CMS Open Payments · Program Year 2024
Maillefer Instruments Holding Sarl
Maillefer Instruments Holding Sarl reported $369,284.76 across General Payments, Research, and Ownership to 26 physicians and teaching hospitals across 26 transactions.
- $369.3K Above-median payer
- All-tracks total
- 26 Below-median volume
- Transactions
- 26 Below-median reach
- Recipients
- +$44.8K
- General Payments vs PY2023
Maillefer Instruments Holding Sarl reported $369,284.76 across all CMS Open Payments tracks (General + Research + Ownership) to 26 physicians and teaching hospitals in Program Year 2024 - ranking #850 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $369,284.76, averaging $14.2K per recipient.
Maillefer Instruments Holding Sarl's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
21/100
Total payments
F
13/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer maillefer-instruments-holding-sarl Maillefer Instruments Holding Sarl
$369.3K · #850/1,925 · 0.0% industry · PY2024
- TOT $369.3K
- RANK #850
- SHARE 0.0%
- TXN 26
- RCP 26
- CAT 4
- GEN $369.3K
- ΔGEN +$44.8K
- TOP1 85.3%
- PY 2024
Volume peers
Nearest volume peer: Trice Medical, Inc. ($369.8K)
Maillefer Instruments Holding Sarl sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Maillefer Instruments Holding Sarl's CMS-reported General Payments increased by $44.8K (+13.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: MAILLEFER INSTRUMENTS HOLDING SARLPY2023: MAILLEFER INSTRUMENTS HOLDING SARLPY2024: Maillefer Instruments Holding Sarl. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $324,510.72
- PY2024
- $369,284.76
What the Data Shows for Maillefer Instruments Holding Sarl
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Maillefer Instruments Holding Sarl that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 4 general-payment categories charted below, "Consulting Fee" is the largest at $251.3K across 4 transactions, 68.1% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 4 types of general payments, Maillefer Instruments Holding Sarl's largest category was "Consulting Fee" at $251.3K - 68.1% of General Payments.
Maillefer Instruments Holding Sarl reports 4 general-payment categories - the top three are Consulting Fee (68.1%), Royalty or License (20.3%), and Travel and Lodging (10.3%). The remaining 1 category make up 1.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Maillefer Instruments Holding Sarl divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $251.3K | 4 | 68.1% |
| Royalty or License | $75.0K | 1 | 20.3% |
| Travel and Lodging | $37.9K | 20 | 10.3% |
| Education | $5.1K | 1 | 1.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $347,443.25 (94.1%) of $369,284.76 in this company's General Payments records across 12 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Maillefer Instruments Holding Sarl
The five named recipients with the highest reported General Payments from this company
- 1
Sergio Kuttler
$315,000.00 across 4 reported transactions
- 2
Asgeir Sigurdsson
$15,765.15 across 3 reported transactions
- 3
George Bruder
$6,227.22 across 3 reported transactions
- 4
Beth Damas
$5,370.75 across 2 reported transactions
- 5
James Gutmann
$5,080.13 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Maillefer Instruments Holding Sarl ranks #850 of 1,925 by total payments (top 44% by spend) but is notably more concentrated than that alone would suggest -- #216 of 1,838 by HHI (top 12% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Aesculap Biologics, LLC : $5.2K total payments, HHI 7394
- Sequence LifeScience, Inc : $194.5K total payments, HHI 7391
- Elekta, Inc. : $3.2M total payments, HHI 7371
- Nanovis LLC : $47.0K total payments, HHI 7351
- Atrility Medical, Inc. : $712.50 total payments, HHI 7341
- Dimension Inx Corp : $1.2K total payments, HHI 7329
- Maillefer Instruments Holding Sarl (this company) : $369.3K total payments, HHI 7308
- Gentuity, LLC : $144.4K total payments, HHI 7294
- Ortho2, LLC : $37.7K total payments, HHI 7276
- Forestadent USA, Inc. : $247.1K total payments, HHI 7271
- Celltrion Healthcare Canada Ltd. : $14.7K total payments, HHI 7263
- Mission Pharmacal Company : $82.4K total payments, HHI 7251
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Maillefer Instruments Holding Sarl's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Maillefer Instruments Holding Sarl.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Maillefer Instruments Holding Sarl.
Showing 6 of 1,924 companies with CMS-reported payment data.
Gamida Cell Inc.
Uswm, LLC
Curiteva, Inc.
American Orthodontics Corporation
Altus Partners. LLC
Put this to use
Maillefer Instruments Holding Sarl ranks #850 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Maillefer Instruments Holding Sarl. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.